New hope for HER2+ breast cancer: phase 3 trial compares BL-M07D1 to standard therapy for residual disease
NCT ID NCT06830889
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1450 women aged 18-75 will be randomly assigned to receive one of the two drugs. The main goal is to see if BL-M07D1 helps prevent cancer from coming back longer than T-DM1.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
Contact
Conditions
Explore the condition pages connected to this study.